Last reviewed · How we verify
JTX-4014
At a glance
| Generic name | JTX-4014 |
|---|---|
| Also known as | PD-1 Inhibitor |
| Sponsor | Jounce Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (PHASE2)
- Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (PHASE1, PHASE2)
- Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JTX-4014 CI brief — competitive landscape report
- JTX-4014 updates RSS · CI watch RSS
- Jounce Therapeutics, Inc. portfolio CI